Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Trial of the ACYW135 Group Meningococcal Polysaccharide-Conjugated Vaccine (CRM197 Vector)
Sponsor: CanSino Biologics Inc.
Summary
This study included 180 trial participants who had previously taken part in the Phase IIIb clinical trial of the ACYW135 group meningococcal polysaccharide-conjugated vaccine (CRM197 carrier) for children aged 4-6 years (Protocol No.: CTP-MCVF-002) and had completed blood sample collection at 90 and 180 days post-vaccination; there were 90 participants in each of the treatment and control groups. All trial participants were required to provide 3.0-4.0 mL of blood samples for immunopersistence assessment at 3 and 5 years post-vaccination, respectively.
Official title: Phase IV Clinical Trial of the ACYW135 Group Meningococcal Polysaccharide-Conjugated Vaccine (CRM197 Vector)
Key Details
Gender
All
Age Range
7 Years - 9 Years
Study Type
OBSERVATIONAL
Enrollment
180
Start Date
2026-09-15
Completion Date
2028-09-15
Last Updated
2026-08-03
Healthy Volunteers
Yes
Conditions
Interventions
Previously vaccinated with MCV4 (CanSino)
3.0 to 4.0 mL of venous blood will be collected for the immunodynamic study at 3 and 5 years after vaccination
Previously vaccinated with MPSV4 (LvZhu)
3.0 to 4.0 mL of venous blood will be collected for the immunodynamic study at 3 and 5 years after vaccination